← Oncology Approval Tracker

FDA DECISION ·

Thalidomide capsules (50, 100 and 200 mg)

thalidomide · Natco Pharma

First generic approvalFirst genericMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Final generic approval of the 50, 100 and 200 mg Thalomid capsule strengths. The oncology use is thalidomide with dexamethasone for newly diagnosed multiple myeloma.

LAMPGEN ANALYSIS

Why it matters

FDA granted final approval for these three strengths in 2026 and approved the 150 mg strength in 2023. The action adds generic capsule strengths for an established myeloma use.

What research teams should watch

Review current product access and applicable safety requirements for teratogenic risk before discussing availability or pharmacy substitution.

PRIMARY RECORDS

Sources